Optimal Number of Hyperbaric Oxygen Treatments for Carbon Monoxide Poisoning
Launched by UNIVERSITY OF ALBERTA · Sep 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best number of hyperbaric oxygen treatments needed for people who have suffered from carbon monoxide poisoning. The researchers want to find out whether one treatment or three treatments, given within 24 hours, leads to better recovery of brain function. Although earlier studies have suggested that both approaches work, there hasn't been a direct comparison to determine which is more effective.
To be eligible for this trial, participants need to be adults over 17 years old who have been referred for treatment due to acute carbon monoxide poisoning. Some individuals, such as those who are unconscious, on a ventilator, pregnant, or have cognitive impairments, won't be able to participate. If you join the study, you will be randomly assigned to receive either one or three hyperbaric oxygen treatments, and the team will monitor your recovery. This research aims to provide clearer guidance on the best treatment for this serious condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult (over 17 years old) patients referred to a Hyperbaric Unit for acute carbon monoxide poisoning.
- Exclusion Criteria:
- • Obtunded
- • Mechanically ventilated
- • Pregnant
- • Incarcerated
- • Cognitively impaired (acutely or chronically)
About University Of Alberta
The University of Alberta, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong commitment to scientific excellence and community health, the university facilitates cutting-edge research across various medical disciplines. Its interdisciplinary approach fosters collaboration among researchers, clinicians, and students, ensuring that clinical trials are designed and conducted with the utmost rigor and ethical standards. By leveraging its extensive resources and expertise, the University of Alberta aims to translate research findings into meaningful advancements in patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Patients applied
Trial Officials
Brian Rowe, MD, MSc, CCFP (EM), FCCP
Study Director
Professor in the Department of Emergency Medicine, Faculty of Medicine & Dentistry, College of Health Sciences, at the University of Alberta
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported